Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis

  • Novartis AG (NYSE:NVS) announced new long-term data from the Phase 3 ASCLEPIOS 1/2 trials and the ALITHIOS open-label extension of Kesimpta (ofatumumab) in multiple sclerosis.
  • The data demonstrated long-term efficacy and safety of Kesimpta with continued reduced risk of disability worsening in relapsing multiple sclerosis following up to four years of treatment. 
  • Kesimpta maintained a similar safety profile as seen in the pivotal Phase 3 trials up to four years of treatment, with no new safety risks identified over the treatment period.
  • Additionally, participants who switched from teriflunomide to Kesimpta in the extension phase demonstrated pronounced reductions in relapses and MRI lesions. 
  • Related: Novartis To Strengthen Pipeline, Boost Productivity With New Organizational Structure.
  • Data from the ongoing KYRIOS open-label study showed that multiple sclerosis patients on Kesimpta can mount an immune response to the COVID-19 mRNA vaccine. 
  • All participants who were vaccinated during continuous Kesimpta treatment developed an immune response one week after the initial vaccination. 
  • Immune response in participants who received a booster during treatment was similar to those who received a booster before treatment. 
  • Price Action: NVS shares are up 0.71% at $87.95 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.